Sign in Subscribe
Diseases

Next-Generation CRISPR Gene Editing Tools in Alzheimer's and Parkinson's Disease Treatment

Strategic Insights

— 1 min read

Advances in gene editing technologies, particularly next-generation CRISPR systems, offer promising solutions for the treatment of Alzheimer's and Parkinson's diseases. These technologies, including base editing, prime editing, and engineered Cas variants, have shown improved fidelity and potential for precise gene correction, transcriptional repression or activation, and modulation of pathological pathways in neurodegeneration. Researchers at the Rungta College of Pharmaceutical Sciences and Research have reviewed the current state of CRISPR-based strategies for advancing neurodegenerative disease management, highlighting the potential for disease modification beyond palliative and symptomatic treatment.

Key Takeaways:

  • Next-generation CRISPR systems, such as base editing and prime editing, have improved fidelity and offer alternative strategies for precise gene correction, transcriptional repression or activation, and modulation of pathological pathways in neurodegeneration.
  • These tools can correct single-nucleotide mutations, reduce pathological protein accumulation, and modulate neuroinflammatory responses, which are integral to the pathogenesis of Alzheimer's disease (AD) and Parkinson's disease (PD).
  • Current clinical investigations aim to translate promising preclinical results into available therapeutic options for AD and PD.
  • The review highlights the biological mechanisms, therapeutic use cases, and current limitations of next-generation CRISPR systems in the context of AD and PD.
  • The research emphasizes the need to address significant challenges, including safe and effective delivery to the CNS, minimizing off-target effects, and addressing ethical concerns.

Statistics:

  • 111: The volume number of the journal Ageing Research Reviews, where the research was published.
  • 102851: The publication number of the research in Ageing Research Reviews.
  • 2025: The year in which the research was published.
  • 814: The page number of the news article in Biotech Week.
  • 2025 AUG 27 (NewsRx): The publication date of the news report.

Sources:

  • Next-generation CRISPR gene editing tools in the precision treatment of Alzheimer's and Parkinson's disease. Ageing Research Reviews, 2025;111:102851.
  • NewsRx. Study Data from Rungta College of Pharmaceutical Sciences and Research Provide New Insights into Gene Editing (Next-generation CRISPR gene editing tools in the precision treatment of Alzheimer's and Parkinson's disease). Biotech Week. August 27, 2025; p 814.

Read more